Sophiris bio inc. (SPHS)
Balance Sheet / Yearly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Dec'12
Current assets:
Cash and cash equivalents

4,251

4,972

7,678

10,998

12,048

13,941

16,286

16,087

16,486

6,824

8,894

12,800

31,055

8,338

5,146

5,881

4,908

7,994

7,994

4,123

16,174

21,255

18,632

14,839

54,739

9,721

Securities available-for-sale

2,050

1,045

1,342

1,541

2,498

4,587

5,767

9,757

12,027

17,205

16,800

16,201

203

0

250

2,500

4,952

5,226

9,048

18,572

12,970

14,379

21,644

33,310

-

-

Prepaid expenses and other current assets

710

305

424

656

888

1,055

-

1,012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other receivables

-

-

-

-

-

-

13

-

62

69

86

128

13

1

0

8

18

7

16

16

18

15

53

48

30

71

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

937

Prepaid expenses

-

-

-

-

-

-

1,009

-

1,118

948

959

846

490

170

430

467

1,506

2,294

2,506

2,825

3,101

3,009

3,882

3,598

3,212

593

Total current assets

7,011

6,322

9,444

13,195

15,434

19,583

23,075

26,856

29,693

25,046

26,739

29,975

31,761

8,509

5,826

8,856

11,384

15,521

19,564

25,536

32,263

38,658

44,211

51,795

57,981

11,322

Property and equipment, net

3

3

3

4

4

3

3

2

3

2

1

4

5

7

12

17

21

26

31

36

40

42

55

78

102

163

Operating lease right-of-use asset

85

116

146

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term assets

-

-

19

-

0

0

19

19

0

0

19

19

0

0

19

19

19

19

19

19

19

19

19

19

19

44

Total assets

7,099

6,441

9,612

13,199

15,438

19,586

23,097

26,877

29,696

25,048

26,759

29,998

31,766

8,516

5,857

8,892

11,424

15,566

19,614

25,591

32,322

38,719

44,285

51,892

58,102

11,529

Current liabilities:
Accounts payable

431

566

802

1,862

400

1,271

1,132

832

737

506

360

459

374

201

395

909

775

776

1,548

2,633

3,871

3,756

4,422

1,470

1,600

1,774

Accrued expenses

745

1,153

1,160

1,192

2,098

2,662

1,824

1,499

1,484

1,154

765

1,762

1,588

734

619

566

1,245

1,659

1,459

2,307

2,912

1,816

1,093

2,181

1,233

2,839

Current portion of promissory note

2,665

2,649

2,633

1,920

1,212

1,548

958

372

-

-

-

0

0

1,879

1,824

1,771

1,719

1,526

1,055

598

154

-

5,284

6,877

6,724

5,895

Current portion of operating lease liability

85

116

124

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

3,926

4,484

4,719

4,974

3,710

5,481

3,914

2,703

2,221

1,660

1,125

2,221

1,962

2,814

2,838

3,246

3,739

3,961

4,062

5,538

6,937

5,572

10,799

10,528

9,557

10,508

Long-term promissory note

3,086

3,758

4,427

5,091

5,751

5,362

5,900

6,435

6,756

-

-

0

0

2,605

3,096

3,572

4,035

4,484

4,920

5,343

5,754

5,876

-

-

1,693

6,126

Warrant liability

2,848

575

846

1,399

9,946

10,099

8,733

10,089

9,491

10,162

13,482

13,396

15,035

2,258

-

0

-

-

-

-

-

-

20

883

1,376

-

Operating lease liability

-

-

22

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation liability

-

-

-

-

-

-

-

-

0

0

23

57

195

102

121

168

42

53

33

22

129

84

181

202

-

-

Total liabilities

9,860

8,817

10,014

11,464

19,407

20,942

18,547

19,227

18,468

11,822

14,630

15,674

17,192

7,779

6,055

6,986

7,816

8,498

9,015

10,903

12,820

11,532

11,000

11,613

12,626

16,634

Commitments and contingencies

-

-

-

-

0

0

0

-

0

0

0

0

-

-

0

0

0

0

-

0

-

-

0

-

0

0

Shareholders’ (deficit) equity:
Common shares, unlimited authorized shares, no par value; 33,572,140 and 30,205,915 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively

131,489

131,247

131,247

131,247

131,247

131,247

131,247

131,247

131,246

131,246

131,246

131,245

131,245

117,745

113,880

113,880

113,095

113,095

113,095

113,095

113,089

113,089

111,204

111,204

111,218

54,215

Common share purchase warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,045

Contributed surplus

27,459

27,128

26,939

26,714

26,531

26,274

26,085

25,854

25,470

24,824

24,336

23,900

23,604

18,983

17,821

17,683

17,670

17,475

17,267

17,053

16,592

16,052

15,286

13,824

13,567

8,379

Accumulated other comprehensive gain

100

99

98

100

99

97

94

97

96

85

86

99

99

99

99

99

100

100

100

99

101

102

101

98

99

-46

Accumulated deficit

-161,809

-160,850

-158,686

-156,326

-161,846

-158,974

-152,876

-149,548

-145,584

-142,929

-143,539

-140,920

-140,374

-136,090

-131,998

-129,756

-127,257

-123,602

-119,863

-115,559

-110,280

-102,056

-

-84,847

-79,408

-

Deficit accumulated during development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

93,306

-

-

73,698

Total shareholders’ (deficit) equity

-2,761

-2,376

-402

1,735

-3,969

-1,356

4,550

7,650

11,228

13,226

12,129

14,324

14,574

737

-198

1,906

3,608

7,068

10,599

14,688

19,502

27,187

33,285

40,279

45,476

-5,105

Total liabilities and shareholders’ (deficit) equity

7,099

6,441

9,612

13,199

15,438

19,586

23,097

26,877

29,696

25,048

26,759

29,998

31,766

8,516

5,857

8,892

11,424

15,566

19,614

25,591

32,322

38,719

44,285

51,892

58,102

11,529